Tempus AI, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Tempus extended its multi-year partnership with Moderna and Merck to support the potential commercialization of V940/mRNA-4157 with KEYTRUDA, including sample logistics and NGS services. Financial details were not disclosed.
Tempus AI received FDA clearance for its AI tool, ECG-MR, which detects potential heart valve issues in at-risk patients. This expands the company's AI software offerings into cardiovascular diagnostics. Analysts project revenues of $2.6B and earnings of $18.7M by 2029, assuming 22% yearly revenue growth. The company aims to integrate its data and software tools across various medical fields, including oncology, genetics, and now cardiology.
Recursion Pharmaceuticals (RXRX) disclosed a two-year, non-exclusive RNA model license agreement with Tempus AI, receiving $12M upfront and access to oncology data. This deal supports drug discovery and AI models, though it's seen as incremental. Analysts forecast $220.9M revenue and $35.5M earnings by 2028, with a 70% upside potential. The agreement aligns with Recursion's data-driven strategy and partnerships with major pharma companies.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning TEM (Tempus AI, Inc.). Coverage has skewed bullish: 5 bullish, 2 neutral, and 1 bearish.
Recent TEM coverage spans financial news, regulation and insider activity.
In the last 30 days, TEM insiders filed 26 SEC Form 4 transactions — no purchases and 26 sales ($37.2M). The most active reporter was LEFKOFSKY ERIC P, CEO and Chairman, with 22 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The partnership deepens Tempus' role in oncology and may boost revenue prospects.
Clearance expands Tempus AI into cardiovascular diagnostics, adding a new revenue stream.
Recursion Pharmaceuticals (RXRX) disclosed a two-year, non-exclusive RNA model license agreement with Tempus AI, receiving $12M upfront and access to oncology data. This deal supports drug discovery and AI models, though it's seen as incremental. Analysts forecast $220.9M revenue and $35.5M earnings by 2028, with a 70% upside potential. The agreement aligns with Recursion's data-driven strategy and partnerships with major pharma companies.
Clearance expands AI‑driven diagnostic offerings, supportive for the stock.
Negative impact from a fund sale.
AlphAI scores every news story that mentions TEM with an AI model for sentiment and relevance, and aggregates insider trades from Tempus AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tempus extended its multi-year partnership with Moderna and Merck to support the potential commercialization of V940/mRNA-4157 with KEYTRUDA, including sample logistics and NGS services. Financial details were not disclosed.
1 min readTempus AI received FDA clearance for its AI tool, ECG-MR, which detects potential heart valve issues in at-risk patients. This expands the company's AI software offerings into cardiovascular diagnostics. Analysts project revenues of $2.6B and earnings of $18.7M by 2029, assuming 22% yearly revenue growth. The company aims to integrate its data and software tools across various medical fields, including oncology, genetics, and now cardiology.
3 min readRecursion Pharmaceuticals (RXRX) disclosed a two-year, non-exclusive RNA model license agreement with Tempus AI, receiving $12M upfront and access to oncology data. This deal supports drug discovery and AI models, though it's seen as incremental. Analysts forecast $220.9M revenue and $35.5M earnings by 2028, with a 70% upside potential. The agreement aligns with Recursion's data-driven strategy and partnerships with major pharma companies.
2 min readEdwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
3 min readARK Invest sold $110.5M in AMD shares and bought $81.6M in Nvidia, along with other tech stocks. AMD is up 183.7% YTD, while Nvidia gained 22.11%. ARK's moves may reflect rebalancing, with no public explanation provided. AMD's market cap briefly hit $1T, and Nvidia announced a $150B buyback.
2 min readSchoenherr Thomas Edward (CEO, Diagnostics) sold 10,281 shares of Tempus AI, Inc. (TEM) at $85.00 ($0.87M total) on 2026-09-25 under a Rule 10b5-1 trading plan.
1 min readTempus AI (TEM) received FDA clearance for Tempus ECG-MR, an AI software detecting moderate or severe mitral regurgitation in 12-lead ECGs. The tool aids in identifying high-risk patients aged 65+ with cardiovascular risk factors. TEM stock is up 1.45% at $86.25.
2 min readArk Invest increased its stakes in Meta Platforms (META) and Rocket Lab (RKLB) last week, purchasing shares worth $38.2M and $25.9M, respectively. The firm also reduced its positions in Tempus AI and CrowdStrike.
1 min readAnalysts initiated coverage on five stocks: Abeona (ABEO) with a $17 target, NexGen (NXE) at $14, Nano Nuclear (NNE) at $33, SanDisk (SNDK) at $2,400, and Tempus (TEM) at $75. Abeona's ZEVASKYN gene therapy, NexGen's uranium project, Nano Nuclear's KRONOS reactor, SanDisk's AI infrastructure, and Tempus's diagnostics business are key focuses.
3 min readTempus AI (TEM) shares rose 7% to $82.24 after reporting Q3 revenue of $382.49M, up 22% YoY, and an adjusted loss of $0.04 per share, beating estimates. CEO Eric Lefkofsky sold 250,000 shares for $19.4M. Analysts have mixed views, with a consensus Hold rating and an average target of $69.63.
2 min read
